Pharmaceuticals, Biotechnology & Life Sciences

Insider buying at Greenland Mines signals confidence in its upgraded Skaergaard project, offering a rare insight into high‑risk exploration and parallels to biotech drug development.

MoonLake insider sales show routine portfolio rebalancing, not panic—CSO Reich Kristian sells 16k shares at $20.01 amid a 63% stock drop.

Explore what MAPLIGHT Therapeutics’ bulk insider selling means for investors—tax‑cover moves, pipeline outlook, and market impact explained.

Insider sale of 10 Lyell Immunopharma shares by Innovative Cellular Therapeutics shows routine liquidity, not a shift in long‑term confidence.

ADMA Biologics insider buy: CFO Terry Kohler’s 143,000‑share purchase signals confidence, hinting at a possible turnaround for the biotech stock.

Insider selling at ATYR Pharma hits record highs, sparking doubts about its pipeline, pricing strategy, and market position—what this means for investors and future drug development.

ADAR1 Capital adds to its stake in InMed Pharmaceuticals, betting on the company’s single‑molecule cannabinoid platform and potential orphan drug breakthroughs.

Opaleye’s July 14 sale of 28,315 Eton Pharma shares taps a price surge, signaling a tactical exit while keeping a residual stake for future upside.

Insider trades reveal a $93 M 10b5‑1 sale at a premium, showing routine portfolio rebalancing amid a bullish cortisol‑modulating biotech market.

Insider buying shows confidence in NUVATION BIO’s NV‑120 pipeline and regulatory momentum—strong Phase II data and potential FDA/EMA approvals could reshape valuation.